Assessment of plasma creatine kinase as biomarker for levodopa-induced dyskinesia in Parkinson's disease.
J Neural Transm (Vienna)
; 126(6): 789-793, 2019 06.
Article
em En
| MEDLINE
| ID: mdl-31098725
We tested in a translational approach the usefulness of plasma creatine kinase (CK) as an objective biomarker for levodopa-induced dyskinesia (LID). Plasma CK levels were measured in five dyskinetic parkinsonian non-human primates (NHP) and in ten PD patients with LID who participated in a treatment trial with simvastatin. Plasma CK levels were increased in dyskinetic NHP and correlated with LID severity while they were not affected by LID severity in PD patients.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Doença de Parkinson
/
Levodopa
/
Creatina Quinase
/
Discinesia Induzida por Medicamentos
/
Antiparkinsonianos
Tipo de estudo:
Clinical_trials
/
Etiology_studies
Limite:
Aged
/
Animals
/
Humans
/
Middle aged
Idioma:
En
Revista:
J Neural Transm (Vienna)
Ano de publicação:
2019
Tipo de documento:
Article